

Haematologica
HAEMATOL/2016/155986
Version 1

Ibrutinib in the real world patient: many lights and some shades

Paolo Ghia and Antonio Cuneo

Disclosures: Paolo Ghia received research funding from GSK, Gilead, Celgene, Roche. He received honoraria from AbbVie, Gilead, Janssen, Adaptive Biotechnologies Roche Antonio Cuneo received Honoraria from Gilead, Janssen, Roche

Contributions: PG and AC elaborated the results of the 2 manuscripts to be commented upon and wrote the paper.